Stockreport

Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates [Yahoo! Finance]

Climb Bio, Inc.  (CLYM) 
PDF Climb Bio, Inc. Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026 Budoprutug clinical trials ongoing in pMN, I [Read more]